Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.72 |
| ▸ | CTSK | P43235 | 6/20 | 0.72 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763600 | 1.00 | CTSS (0.72) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL26270 | 1.00 | CTSS (0.72) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL21447323 | 0.89 | CTSS (0.69) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL16448051 | 0.89 | ACE (0.62) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL25532536 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL5887611 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL5887609 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL11728465 | 0.89 | CTSS (0.61) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL2617401 | 0.88 | CTSS (0.67) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL539218 | 0.88 | CTSS (0.67) | CTSSCTSKACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574245-A | 4-10Preparation method of boric acid group-L-phenylalanine | 四川瑶天纳米科技有限责任公司 | 2021-03-30 | — | — | CN | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | disclosed |
| EP-0991619-A1 | INHIBITORS OF $g(a) 4?$g(b) 1?MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-6008240-A | AN ANTAGONIST OF HISTAMINE H3 RECEPTORS; FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE (HYPER OR HYPOTENSION), GASTROINTESTINAL DISORDERS, CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1998058902-A1 | INHIBITORS OF α4β1MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-30 | — | — | WO | disclosed |
| EP-0041286-B1 | LH-RH ANTAGONISTS | Schally, Andrew Victor (US) | 1984-08-15 | — | — | EP | disclosed |
| US-4431635-A | PEPTIDE ANALOGS OF LUTEINIZING HORMONE RELEASING HORMONE; GLANDULAR DISORDERS; ANTICARCINOGENIC AGENTS | COY DAVID HOWARD | 1984-02-14 | — | — | US | disclosed |
| US-4317815-A | PEPTIDE ANALOGS OF LUTENIZING HORMONE RELEASING HORMONE | ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND, THE, A CORPORATE ENTITY OF TULANE UNIVERSITY A CORP. OF LA. | 1982-03-02 | — | — | US | disclosed |
| EP-0041286-A1 | LH-RH antagonists | Schally, Andrew Victor (US) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | CTSS 614/4885CTSK 583/4885ACE 3545/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | CTSS 3439/4885CTSK 3867/4885ACE 1258/4885 |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | CTSS 3065/4885CTSK 3616/4885ACE 1510/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | CTSS 565/4885CTSK 868/4885ACE 3189/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | CTSS 1137/4885CTSK 2422/4885ACE 565/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | CTSS 2859/4885CTSK 3873/4885ACE 663/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | CTSS 823/4885CTSK 2120/4885ACE 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.